Richmond, British Columbia - Liberty Biopharma Inc. (“Liberty Biopharma” or the “Company”) (TSXV: LTY) announces that it has closed a non-brokered private placement consisting of the issuance of 2,580,000 common shares to one (1) investor at a price of $0.15 per common share for gross proceeds of $387,000 (“Private Placement”).
A commission of 258,000 common shares of the Company will be issued to Red Rock Global Capital Ltd. of New York, New York, the arm’s length finder for arranging the Private Placement. The commission is subject to acceptance by the TSX Venture Exchange (the “Exchange”).
The Private Placement is subject to acceptance by the Exchange. All securities issued under the Private Placement will be subject to a hold period expiring four months and one day from the date of issuance.
About Liberty Biopharma Inc.
Liberty Biopharma is a medical digital technology and biopharmaceutical company active in global strategic partnerships and in-licensing of technologies and assets for rapid growth and high value solutions.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly